OWL-CGM: Optimizing Weight Loss. Can Continuous Glucose Monitoring Play a Role
Study Details
Study Description
Brief Summary
The goal of this clinical trial is to determine the potential effectiveness of adding Continuous Glucose Monitoring to a personalized weight loss maintenance program in improving weight loss maintenance.
The main questions it aims to answer are:
-
What is the feasibility and acceptability of wearing a continuous glucose monitoring device in people maintaining weight loss?
-
Is using continuous glucose monitoring will help to change the food and physical activity behavior in people maintaining weight loss?
Participants will be randomized into control and intervention groups where the researchers will compare the effects of wearing continuous glucose monitoring devices on behavior change in both groups.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The study is a 24-week study conducted at the University of Glasgow. It is a randomized, non-blinded, feasibility trial with 48 adults randomized into one of two groups (24 adults in each group):
-
Personalized Weight Management Group (PWM): The group will receive a personalized diet and physical activity plan and five one-to-one online support meetings with a trained dietitian over the first 12 weeks of the program (in weeks 1, 2, 4, 8, and 12). The participants also will be given an evidence-based weight loss maintenance information booklet and advice (e.g.: dietary advice, physical activity recommendation, the importance of self-monitoring weight, diet, and physical activity). Participants will be asked to self-manage during weeks 12 - 24 and asked to maintain the diet, PA recommendations, and monitoring based on the advice and training provided in the first 12 weeks of the program.
-
PWM + CGM: This group will receive the same support as the PWM group. The participants also will be given an evidence-based weight loss maintenance information booklet and advice (e.g.: dietary advice, physical activity recommendation, the importance of self-monitoring weight, diet, physical activity, and glucose level). In addition, participants will be provided with a CGM device and guidance on how to use this to support weight loss maintenance. They will be provided with CGM devices for the whole study duration.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Personalized Weight Management group (PWM) The group will receive a personalized diet and physical activity plan and five one-to-one online support meetings with a trained dietitian over the first 12 weeks of the program (in weeks 1, 2, 4, 8, and 12). The participants also will be given an evidence-based weight loss maintenance information booklet and advice (e.g.: dietary advice, physical activity recommendation, the importance of self-monitoring weight, diet, and physical activity). Participants will be asked to self-manage during weeks 12 - 24 and asked to maintain the diet, PA recommendations, and monitoring based on the advice and training provided in the first 12 weeks of the program. |
|
| Experimental: PWM + Continuous Glucose Monitoring (CGM) This group will receive the same support as the PWM group. The participants also will be given an evidence-based weight loss maintenance information booklet and advice (e.g.: dietary advice, physical activity recommendation, the importance of self-monitoring weight, diet, physical activity, and glucose level). In addition, participants will be provided with a CGM device and guidance on how to use this to support weight loss maintenance. They will be provided with CGM devices for the whole study duration. |
Device: Continuous Glucose Monitoring device
A small wearable transdermal sensor that tracks glucose levels in interstitial fluid by taking measurements at regular and frequent intervals throughout the day and night.
|
Outcome Measures
Primary Outcome Measures
- Research recruitment rate [24 weeks]
The number of adults being recruited over the course of recruitment phase.
- Research retention rate [24 weeks]
Retention is the number of participants that remain till the end of the trial at the end of 24 weeks.
- Adherence of CGM use [24 weeks]
The proportion of days for which valid CGM data are obtained from the CGM group.
- Changes in dietary intake [24 weeks]
Dietary Intake monitored for 3 days at 0, 12, 24 weeks using the MyFood24 online diaries where the participants will have to log their daily dietary intake.
- Changes in physical activity [24 weeks]
Physical Activity level monitored objectively for a day using an accelerometer at 0, 12, 24 weeks.
- Changes in weight [24 weeks]
Weight will be monitored using weight scale from baseline Week 0, Week 12 and Week 24
- Changes in body composition [24 weeks]
Body composition will be measured using bioelectrical impedance at Week 0, 12, 24
Secondary Outcome Measures
- Qualitative evaluation of participant's experiences [24 weeks]
Qualitative evaluation of participant's experiences will be conducted through a semi structured interview with 8-12 of participants
- Changes in biomarkers of cardio-metabolic disease risk [24 weeks]
Biomarkers measurement will be measured at the 0, 12, 24 weeks. The blood will be taken from the participant to test on biomarkers of cardio-metabolic risk which include Fasting insulin level, fasting glucose, HbA1c, triglyceride, cholesterol
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥18 years old.
-
Intentionally lost ≥5 kg within the past 6 months
-
Have a BMI of >25kg/m2 prior to weight loss
-
Have access to and be able to use a smartphone or tablet running iOS or Android and be able to use the Freestyle Libre app and MyFood24 app OR access and ability to use a telephone.
-
Participants should be willing to use CGM.
-
Participants must be able to read, understand and communicate in English
Exclusion Criteria:
-
Have been diagnosed with Type 1 and Type 2 Diabetes
-
Pregnant or planning pregnancy in the next 6 months, or currently breastfeeding.
-
Participants who are currently on any pharmacological treatments for weight loss or any drugs may affect body weight.
-
Participants who have previously had bariatric surgery for weight loss including gastric bypass and sleeve gastrectomy.
-
Participants with known hypersensitivity to CGM sensors.
-
Participants with any other serious medical condition, in the opinion of the investigators, would compromise their safety or adherence to the study.
-
Participants diagnosed with an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or purging disorder).
-
Participants who lack capacity or are unable to read or understand written or verbal instructions in English.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Glasgow | Glasgow | United Kingdom | G128QQ |
Sponsors and Collaborators
- University of Glasgow
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 200220068